产品详情
Targets
Target | Value |
---|---|
EGFR | IC50: 38.5nM |
Src | IC50: 282nM |
MEK/ERK | IC50: 800nM |
ErbB2 | IC50: 1.255μM |
Raf | IC50: 3.353μM |
c-Met | IC50: 4.1μM |
CDK4 | IC50: >20μM |
In vitro | DMSO | 12 mg/mL (25.64 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 21.37 mL | 106.86 mL | 213.72 mL |
0.5 mM | 4.27 mL | 21.37 mL | 42.74 mL |
1 mM | 2.14 mL | 10.69 mL | 21.37 mL |
5 mM | 0.43 mL | 2.14 mL | 4.27 mL |
*The above data is based on the productmolecular weight 467.9 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
目录号 | A10706 |
---|---|
作用机制 | Inhibitor (抑制剂) |
M. Wt | 467.9 |
Formula | C24H23ClFN5O2 |
Purity | >99% |
Storage | Store lyophilized at -20ºC, keep desiccated. |
CAS No. | 257933-82-7 |
Synonyms | WAY-EKB 569 |
SMILES | CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)F)Cl)C#N)NC(=O)/C=C/CN(C)C |
产品标签
Product Questions
Product Questions
PD153035 (HCl salt)
PD153035 (HCl salt)是EGFR酪氨酸激酶活性的极其有效和特异的抑制剂。
CO-1686 (Rociletinib, AVL-301)
CO-1686是一种新型的口服靶向共价(不可逆)抑制剂,可抑制表皮生长因子受体(EGFR)的致癌突变形式,目…
Canertinib (CI-1033)
Canertinib (CI-1033)是一种不可逆的酪氨酸激酶抑制剂,对EGFR(IC50 0.8 nM),HER-2(IC50 19 nM)和ErbB-4(IC50 7 nM)…
Mubritinib (TAK 165)
Mubritinib (TAK 165)是一种有效的EGFR和p34cdc2抑制剂,IC50分别为6 nM和0.2 ?M。Mubritinib(TAK 165)也抑制p33cdk2和p33cd…
CL-387785 (EKI-785)
CL-387785是EGFR的不可逆抑制剂,IC50为370+/-120 pM;能够在功能水平上克服由T790M突变引起的抗药性。
PKC 412 (Midostaurin)
PKC 412 (Midostaurin)是一种广谱蛋白激酶抑制剂。抑制常规PKC亚型α/β/γ,PDFRβ,VEGFR2,Syk,Flk-1,Flt3,Cdk1/B,…
PF299804 (Dacomitinib, PF299)
PF299804是一种有效的,可口服的酪氨酸激酶人表皮生长因子受体(HER)1(EGFR),HER2和HER4不可逆抑制剂。